6-(methanesulfonamido)oxindole | 258831-95-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(methanesulfonamido)oxindole
• 英文别名: 6-Methylsulfonylamino-2-oxindole；N-(2-oxo-1,3-dihydroindol-6-yl)methanesulfonamide
• CAS: 258831-95-7
• 化学式: C₉H₁₀N₂O₃S
• 分子量: 226.256
• InChiKey: HWRRRQBVCDXNKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(methanesulfonamido)oxindole 、 甲酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors

  摘要：

  A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel, selective compounds, that inhibit JNK3, but not p38 MAP kinase and provided key insights into understanding the behavior of gatekeeper residue methionine-146 in determining target selectivity for this series.

  DOI：

  10.1016/j.bmcl.2009.03.043
• 作为产物：
  描述：

  在 铁粉 、 溶剂黄146 作用下， 生成 6-(methanesulfonamido)oxindole
  参考文献：
  名称：

  Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors

  摘要：

  A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel, selective compounds, that inhibit JNK3, but not p38 MAP kinase and provided key insights into understanding the behavior of gatekeeper residue methionine-146 in determining target selectivity for this series.

  DOI：

  10.1016/j.bmcl.2009.03.043

文献信息

• [EN] PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE 2-INDOLINONE A SUBSTITUTION PYRROLE
  申请人：SUGEN, INC.

  公开号：WO1999061422A1

  公开（公告）日：1999-12-02

  (EN) The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.(FR) La présente invention concerne de nouveaux composés 2-indolinone à substitution pyrrole, ainsi que les sels physiologiquement acceptables et les promédicaments de ceux-ci. Ces nouveaux composés, destinés à moduler l'activité de la protéine kinase, sont donc utiles pour prévenir et traiter les dysfonctionnements cellulaires liés à la protéine kinase, par exemple le cancer.

  (中文) 本发明涉及新型吡咯取代的2-吲哚酮化合物及其生理上可接受的盐和前药，这些化合物可以调节蛋白激酶的活性，因此预计在预防和治疗与蛋白激酶相关的细胞疾病，如癌症方面有用。
• Pyrrole substituted 2-indolinone protein kinase inhibitors
  申请人：SUGEN, INC.

  公开号：US20030105151A1

  公开（公告）日：2003-06-05

  The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及新型吡咯取代的2-吲哚酮化合物及其生理上可接受的盐和前药，可以调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• 3-methylidenyl-2-indolinone modulators of protein kinase
  申请人：Sugen, Inc.

  公开号：US20040024010A1

  公开（公告）日：2004-02-05

  The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及新型的3-甲基亚烯基-2-吲哚酮化合物及其生理上可接受的盐和前药，这些化合物可调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用途。
• 3-Methylidenyl-2-indolinone modulators of protein kinase
  申请人：Sugen, Inc.

  公开号：US06531502B1

  公开（公告）日：2003-03-11

  The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及新型的3-甲基亚乙烯基-2-吲哚酮化合物及其生理上可接受的盐和前药，其调节蛋白激酶活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS
  申请人：Sugen, Inc.

  公开号：EP1082305A1

  公开（公告）日：2001-03-14